27,277 Shares in Nightstar Therapeutics PLC (NITE) Purchased by Virtus ETF Advisers LLC

Virtus ETF Advisers LLC bought a new stake in Nightstar Therapeutics PLC (NASDAQ:NITE) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 27,277 shares of the company’s stock, valued at approximately $314,000. Virtus ETF Advisers LLC owned approximately 0.10% of Nightstar Therapeutics at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Bank of America Corp DE purchased a new position in shares of Nightstar Therapeutics during the second quarter worth approximately $132,000. Harel Insurance Investments & Financial Services Ltd. purchased a new position in shares of Nightstar Therapeutics in the third quarter worth $169,000. Janney Montgomery Scott LLC purchased a new position in shares of Nightstar Therapeutics in the third quarter worth $204,000. JPMorgan Chase & Co. purchased a new position in shares of Nightstar Therapeutics in the third quarter worth $214,000. Finally, Marshall Wace LLP purchased a new position in shares of Nightstar Therapeutics in the third quarter worth $1,205,000. 37.66% of the stock is currently owned by institutional investors and hedge funds.

In related news, CEO David A. Fellows sold 8,733 shares of Nightstar Therapeutics stock in a transaction on Monday, January 7th. The shares were sold at an average price of $12.98, for a total value of $113,354.34. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Gregory Scott Robinson sold 14,764 shares of Nightstar Therapeutics stock in a transaction on Wednesday, January 2nd. The shares were sold at an average price of $11.15, for a total transaction of $164,618.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 24,328 shares of company stock worth $291,734.

Several research analysts recently commented on the stock. Zacks Investment Research downgraded shares of Nightstar Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 16th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $42.00 target price (up from $36.00) on shares of Nightstar Therapeutics in a research note on Thursday, January 10th. UBS Group assumed coverage on shares of Nightstar Therapeutics in a research note on Friday, January 4th. They issued a “buy” rating and a $21.00 target price on the stock. Finally, Barclays assumed coverage on shares of Nightstar Therapeutics in a research note on Monday, December 17th. They issued an “overweight” rating and a $28.00 target price on the stock. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Nightstar Therapeutics presently has an average rating of “Buy” and a consensus target price of $31.00.

NASDAQ:NITE traded down $0.38 during trading hours on Wednesday, hitting $14.03. The company had a trading volume of 799 shares, compared to its average volume of 54,686. The stock has a market cap of $404.92 million, a P/E ratio of -8.61 and a beta of 3.15. Nightstar Therapeutics PLC has a 52 week low of $9.59 and a 52 week high of $29.55.

Nightstar Therapeutics (NASDAQ:NITE) last released its quarterly earnings results on Tuesday, November 13th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.13. Analysts predict that Nightstar Therapeutics PLC will post -1.45 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “27,277 Shares in Nightstar Therapeutics PLC (NITE) Purchased by Virtus ETF Advisers LLC” was originally reported by Markets Daily and is the property of of Markets Daily. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.themarketsdaily.com/2019/02/13/27277-shares-in-nightstar-therapeutics-plc-nite-purchased-by-virtus-etf-advisers-llc.html.

About Nightstar Therapeutics

Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia.

Featured Article: Outstanding Shares, Buying and Selling Stocks

Want to see what other hedge funds are holding NITE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nightstar Therapeutics PLC (NASDAQ:NITE).

Institutional Ownership by Quarter for Nightstar Therapeutics (NASDAQ:NITE)

Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply